AnPac Bio: More than doubles as co forecasts 100% revenue growth in 2020

Fresh2

25/11/2020 13:30

** U.S.-listed shares of Chinese biotech co  ANPC.O  rise
111.9% to $7.42 in premarket trade
    ** Co says it has experienced strong demand for its cancer
screening tests and set a record in paid test volume in Q3
 urn:newsml:reuters.com:*:nGNX2nZDdt
    ** For FY20, ANPC estimates a revenue growth of 100% yr/yr
with rev range of $3 mln-$3.3 mln vs 2019 rev of $1.6 mln
    ** Avg selling price in 2020 is expected to increase yr/yr,
contributing to higher revenue growth forecast - ANPC
    ** ANPC has two certified clinical labs in China and one in
the United States, where it performs a suite of cancer screening
and detection tests
    ** U.S. stock down 69% since Jan. 30 IPO

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))